Cancer Genetics (NASDAQ:CGIX) Shares Down 7.1%

Share on StockTwits

Cancer Genetics Inc (NASDAQ:CGIX) dropped 7.1% during mid-day trading on Tuesday . The stock traded as low as $0.13 and last traded at $0.13, approximately 2,007,160 shares traded hands during mid-day trading. A decline of 1% from the average daily volume of 2,026,844 shares. The stock had previously closed at $0.14.

The company has a debt-to-equity ratio of 0.24, a current ratio of 0.36 and a quick ratio of 0.36. The firm’s 50 day simple moving average is $0.16.

Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings data on Monday, May 20th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $6.84 million during the quarter. Cancer Genetics had a negative net margin of 77.28% and a negative return on equity of 175.72%.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in shares of Cancer Genetics by 38.4% in the second quarter. Renaissance Technologies LLC now owns 2,777,125 shares of the medical research company’s stock valued at $453,000 after purchasing an additional 769,896 shares in the last quarter. Perkins Capital Management Inc. grew its position in shares of Cancer Genetics by 649.9% in the first quarter. Perkins Capital Management Inc. now owns 3,136,528 shares of the medical research company’s stock valued at $753,000 after purchasing an additional 2,718,278 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Cancer Genetics in the first quarter valued at approximately $48,000. Finally, Geode Capital Management LLC grew its position in shares of Cancer Genetics by 106.6% in the fourth quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 114,448 shares in the last quarter. Institutional investors and hedge funds own 10.56% of the company’s stock.

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Further Reading: 52-Week High/Low

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.